通过固体药物纳米颗粒在固定的组合下持续降低眼内压力,用于对玻璃眼瘤进行治疗
Da Huang1,2, Pedro Norat3, Lin Qi2
1College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, 350108, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|June 14, 2024
概括
一种新的可扩展方法可以创建固体药物纳米粒子 (SDN) 来治疗青光眼. 这些布里莫尼丁/贝塔克索洛尔SDN可以改善药物输送,并通过眼滴持续降低眼内压力.
科学领域:
- 眼科医生 眼科 眼科
- 纳米技术纳米技术
- 药品制造 药品制造 药品制造
背景情况:
- 对玻璃眼的局部药物输送具有挑战性.
- 纳米粒子配方表现有希望,但面临诸如复杂的准备和批量不一致等障碍.
- 需要有效地提供联合抗葡萄糖瘤药物.
研究的目的:
- 开发一种可扩展的固体药物纳米颗粒 (SDN) 制造战略,用于增强局部玻璃眼治疗.
- 为了创建统一的,固定组合的布里莫尼丁/贝塔克索洛尔SDN (BM/BX SDN),提高批次的一致性.
- 评估BM/BX SDNs在青光眼治疗中的有效性和安全性.
主要方法:
- 使用连续工艺制造均的固定组合BM/BX SDN,使用三糖作为冷保护剂.
- 对复制的BM/BX SDNs进行溶液清晰度,均性,细胞毒性和刺激的评估.
- 评估 BM/BX SDNs 的角膜透率,ex vivo 和 in vivo.
- 测量BM/BX SDNs的眼内压 (IOP) 降低效应在正常压力大鼠和青光眼小鼠中.
主要成果:
- 一个可扩展的连续过程产生了统一的BM/BX SDN,并具有良好的批量一致性.
- 复制的BM/BXSDN形成了透明,均的溶液,细胞毒性和刺激是可以忽略不计的.
- 与水友性药物对应物相比,BM/BX SDNs显示显著增强角膜透率 (2-3倍).
- 在正常压力和玻璃眼动物模型中都观察到一致的IOP降低效应.
结论:
- 开发的可扩展的制造策略对于生产稳定,固定组合的玻璃眼病药物纳米粒子是有效的.
- BM / BX SDN 提供优越的角膜透率和一致的 IOP 降低,用于局部玻璃眼治疗.
- 这种方法具有显著的潜力,可以通过先进的眼滴配方来改善青光眼的治疗.
相关概念视频
Open Angle Glaucoma: Treatment
427
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
427
Angle Closure Glaucoma: Treatment
473
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
473
Glaucoma: Overview
541
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
541
Drug Delivery: Miscellaneous Routes
338
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
338
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166


